Figure 3
ONO-1301 increased mature BDNF and ATP production in the spinal cord of mSOD1G93A mice. (a) Relative mRNA expression levels of cyclooxygenase 2 (COX2), interferon gamma (IFN-g), interleukin 1 beta (IL-1), nitric oxide synthase 2 (NOS), brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), hepatocyte growth factor (HGF), vascular endothelial growth factor receptor (VEGFR), cAMP response element binding protein (Creb), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1a) in the spinal cord of 120-day-old ONO-1301-MS–treated mSOD1G93A mice and vehicle-treated controls. (b) Western blot analysis revealed significantly increased level of mature BDNF in the spinal cords of 120-day-old ONO-1301-MS–treated mSOD1G93A mice relative to vehicle-treated mSOD1G93A mice. (c) Relative mRNA expression levels of caspase-9 (Casp9) and cyclooxygenase 1 (COX1) in the spinal cord of 120-day-old ONO-1301-MS–treated mSOD1G93A mice and vehicle-treated controls. (d) Relative mRNA expression levels of Apoptotic protease activating factor 1 (Apaf1), caspase 3 (Casp3), B-cell lymphoma 2 (Bcl2), B-cell lymphoma-extra large (Bcl-xL), and BCL2 associated X (Bax) in the spinal cord of 120-day-old ONO-1301-MS–treated mSOD1G93A mice and vehicle-treated controls. (e) ATP concentrations in spinal cords of ONO-1301-MS–treated mSOD1G93A mice and vehicle-treated mSOD1G93A mice at 12 weeks of age (n = 3 mice per group) after 3 weeks of treatment. The values were normalized to basal levels in wild-type mice or in vehicle-treated mSOD1G93A mice. Data are expressed as the mean ± SEM. *P < 0.05.
